Ultragenyx Pharmaceutical Inc.

RARE

US90400D1081

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
44.24 ^USD	+0.89%		+4.41%	-7.49%

Apr. 22	RBC Starts Ultragenyx Pharmaceutical at Outperform, Speculative Risk With $77 Price Target, Sees 'Particularly Attractive' Risk/Reward	MT
Apr. 15	Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup	DJ

Ultragenyx Pharmaceutical Inc. Reports Unaudited Preliminary Sales Results for 2023

January 07, 2024 at 11:00 am EST

Ultragenyx Pharmaceutical Inc. reported unaudited Preliminary sales results for 2023. For the year, company reports total Revenue was $430 million - $435 million.

Latest news about Ultragenyx Pharmaceutical Inc.

RBC Starts Ultragenyx Pharmaceutical at Outperform, Speculative Risk With $77 Price Target, Sees 'Particularly Attractive' Risk/Reward	Apr. 22	MT
Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup	Apr. 15	DJ
Ultragenyx Says Data From Phase 1/2 Trial of GTX-102 to Treat Angelman Syndrome Showed 'Meaningful Improvement'	Apr. 15	MT
Sector Update: Health Care Stocks Advance Premarket Monday	Apr. 15	MT
Transcript : Ultragenyx Pharmaceutical Inc. - Special Call	Apr. 15
Ultragenyx Pharmaceutical Inc. Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102	Apr. 15	CI
JPMorgan Adjusts Price Target on Ultragenyx Pharmaceutical to $92 From $88, Maintains Overweight Rating	Mar. 18	MT
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:00 AM	Mar. 13
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 04:20 PM	Mar. 12
Ultragenyx Pharmaceutical Insider Sold Shares Worth $574,644, According to a Recent SEC Filing	Mar. 12	MT
Transcript : Ultragenyx Pharmaceutical Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 09:10 AM	Mar. 04
Canaccord Genuity Adjusts Ultragenyx Pharmaceutical's Price Target to $111 From $110, Keeps Buy Rating	Feb. 21	MT
Sector Update: Health Care Stocks Gain Pre-Bell Friday	Feb. 16	MT
Wedbush Lifts Ultragenyx Pharmaceutical's PT to $48 From $47, Notes Fuller Catalyst Lineup for 2024; Keeps Neutral Rating	Feb. 16	MT
Ultragenyx Pharmaceutical Q4 Loss Narrows, Revenue Rises; 2024 Revenue Guidance Set	Feb. 15	MT
Transcript : Ultragenyx Pharmaceutical Inc., Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Posts Q4 Revenue $127.4M	Feb. 15	MT
Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year 2024	Feb. 15	CI
Ultragenyx Pharmaceutical Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 15	CI
Ultragenyx Says UX111 Treatment Results Correlate With Improved Cognitive Function	Feb. 06	MT
Ultragenyx Pharmaceutical Inc. Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)	Feb. 06	CI
Ultragenyx Pharmaceutical's Angelman Syndrome Potential Treatment Receives European Medicines Agency Priority Designation	Feb. 06	MT
Ultragenyx Pharmaceutical Inc. Receives PRIME Designation from European Medicines Agency for GTX-102 for the Treatment of Angelman Syndrome	Feb. 05	CI
Ultragenyx Pharmaceutical Doses All Patients in Stage 1 Cohorts of Trial Evaluating Wilson Disease Therapy	Jan. 26	MT
Ultragenyx Pharmaceutical Inc. Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease	Jan. 25	CI

Chart Ultragenyx Pharmaceutical Inc.

Duration

Period

More charts

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Companyâs four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Ultragenyx Pharmaceutical Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

44.24 USD

Average target price

89.52 USD

Spread / Average Target

+102.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ULTRAGENYX PHARMACEUTICAL INC.	-7.49%	3.64B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs